Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q2 2024 vs. Q1 2024
How the institutions holding Jasper Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 61 | 69 | +8 |
| Shares | 13.0M | 14.6M | +1.54M (+11.8%) |
| Value | $380.2M | $329.8M | −$50.4M (−13.3%) |
New holders (26)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (18)
Institutions that held Jasper Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Jane Street Group, LLC | 41,894 | $1.23M |
| Bank of Montreal | 69,100 | $811.9K |
| HRT Financial LP | 23,271 | $683.0K |
| Concurrent Investment Advisors, LLC | 20,409 | $599.2K |
| Man Group plc | 20,357 | $597.7K |
| Citadel Advisors LLC | 16,210 | $475.9K |
| Marshall Wace, LLP | 13,449 | $394.9K |
| Landscape Capital Management, L.L.C. | 11,397 | $334.6K |
| Virtu Financial LLC | 10,410 | $306.0K |
| Cubist Systematic Strategies, LLC | 10,250 | $300.9K |
| Balyasny Asset Management LLC | 8,417 | $247.1K |
| Brevan Howard Capital Management LP | 8,378 | $246.0K |
| Susquehanna International Group, LLP | 8,084 | $237.3K |
| Point72 Asia (Singapore) Pte. Ltd. | 8,002 | $234.9K |
| Atom Investors LP | 7,373 | $216.5K |
| ADAR1 Capital Management, LLC | 2,406 | $70.6K |
| BFSG, LLC | 10 | $294 |
| Macquarie Group Ltd | 697 | $20 |